Contributions
Abstract: P775
Type: Poster
Abstract Category: Therapy - symptomatic - Quality of life
Background: Differences between patient and health professional perception of chronic disease have been studied, although little is known about perception of disease severity in people with multiple sclerosis (PwMS). Decision-making should be a shared process between patients and health professionals in order to achieve an agreement on medical decisions.
We have to be aware that discrepancies between health professionals and PwMS in disease severity perception may arise. Taking into account these discrepancies may help to avoid possible conflict in the decision making process.
Objective: To assess the concordance between disease severity perception and objective clinical severity.
To analyze the influence of personality traits, depression, cognitive impairment and clinical characteristics in patients" disease perception.
Methods: An observational pilot study was performed in a Multiple Sclerosis unit. Patients were asked to evaluate their disease severity with Visual Analogue Scale (VAS), depression with Patient Health Questionnaire (PHQ-9), personality with Ten Item Personality Measure (TIPI) and cognition with Verbal Fluency Test (FAS). Age, sex, Multiple Sclerosis Severity Score (MSSS), Expanded Disability Status Scale (EDSS), time from the last relapse and disease duration were also collected.
A Pearson correlation test was performed between MSSS (objective clinical severity) and VAS (patient perception). A linear regression model was performed to explain the difference between VAS scale and MSSS.
Results: 30 patients were selected, 25 women and 5 men. Patients characteristics were: Mean age 46 (±10.5) years, EDSS 3.4 ( ±2.2), disease duration 17 (±10) years, MSSS 3.68 (±2.79).
Only MSSS independently correlated with the difference between perception and objective clinical severity (VAS-MSSS): patients with higher MSSS showed more negative values in the difference between VAS-MSSS. For each one MSSS point increase, this difference increased -0.464 (95% CI -0.449 to -0.058). MSSS scores explained 21.5% of this difference variability.
Conclusion: Patients with higher MSSS scores show a more optimistic perception of their disease.
This perception it is not influenced by personality traits, depression, cognitive impairment or clinical characteristics.
Disclosure:
I.León received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
L.Bau received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
E.Matas received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono. L.Romero-Pinel received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
MA Mañé-Martínez received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
S.Macho received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono
A. Martínez-Yélamos received received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
S. Martínez-Yélamos received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
Abstract: P775
Type: Poster
Abstract Category: Therapy - symptomatic - Quality of life
Background: Differences between patient and health professional perception of chronic disease have been studied, although little is known about perception of disease severity in people with multiple sclerosis (PwMS). Decision-making should be a shared process between patients and health professionals in order to achieve an agreement on medical decisions.
We have to be aware that discrepancies between health professionals and PwMS in disease severity perception may arise. Taking into account these discrepancies may help to avoid possible conflict in the decision making process.
Objective: To assess the concordance between disease severity perception and objective clinical severity.
To analyze the influence of personality traits, depression, cognitive impairment and clinical characteristics in patients" disease perception.
Methods: An observational pilot study was performed in a Multiple Sclerosis unit. Patients were asked to evaluate their disease severity with Visual Analogue Scale (VAS), depression with Patient Health Questionnaire (PHQ-9), personality with Ten Item Personality Measure (TIPI) and cognition with Verbal Fluency Test (FAS). Age, sex, Multiple Sclerosis Severity Score (MSSS), Expanded Disability Status Scale (EDSS), time from the last relapse and disease duration were also collected.
A Pearson correlation test was performed between MSSS (objective clinical severity) and VAS (patient perception). A linear regression model was performed to explain the difference between VAS scale and MSSS.
Results: 30 patients were selected, 25 women and 5 men. Patients characteristics were: Mean age 46 (±10.5) years, EDSS 3.4 ( ±2.2), disease duration 17 (±10) years, MSSS 3.68 (±2.79).
Only MSSS independently correlated with the difference between perception and objective clinical severity (VAS-MSSS): patients with higher MSSS showed more negative values in the difference between VAS-MSSS. For each one MSSS point increase, this difference increased -0.464 (95% CI -0.449 to -0.058). MSSS scores explained 21.5% of this difference variability.
Conclusion: Patients with higher MSSS scores show a more optimistic perception of their disease.
This perception it is not influenced by personality traits, depression, cognitive impairment or clinical characteristics.
Disclosure:
I.León received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
L.Bau received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
E.Matas received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono. L.Romero-Pinel received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
MA Mañé-Martínez received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
S.Macho received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono
A. Martínez-Yélamos received received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
S. Martínez-Yélamos received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.